Fiber fix for peanut allergy? small study tests prebiotic boost to OIT
NCT ID NCT05138757
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This small pilot study tested whether adding a prebiotic fiber (a type of plant fiber found in grocery stores) to peanut oral immunotherapy could help children aged 4 to 17 with peanut allergy tolerate more peanut protein with fewer side effects. Twenty children participated, and the study looked at safety and how many could eat at least 2044 mg of peanut protein with only mild symptoms after 12 months. The results are preliminary and need larger studies to confirm.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- prebiotic fiber
- What this could lead to
- If it works, this could point toward a way to make peanut oral immunotherapy safer and more effective by adding a simple dietary fiber.
- What could go wrong
- This is a very small pilot study with only 20 participants, so results may not apply broadly. The prebiotic is not FDA-approved for this use, and side effects like stomach issues are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1/2
Runs two stages together: safety and dose first, then whether the treatment works.
- Participants
-
20 people
The number who actually took part.
- Started
-
Nov 2021
- Finished
-
Mar 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
4 to 17 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 4 to 17 (inclusive) * A convincing clinical history of peanut allergy * Immune markers consistent with peanut allergy * Serum IgE to peanut of \>0.35 kUA/L and a skin prick test to peanut \>8mm greater than the negative saline control -or- * Serum IgE to peanut of \>5 kUA/L and a mean peanut wheal diameter on skin prick test 3 to 8mm greater than the negative saline control -or- * Serum IgE to peanut of \>14 kUA/L and mean peanut wheal diameter on skin prick test 3mm greater than the negative saline control * Experience dose-limiting symptoms at or before 100mg challenge dose of peanut protein on screening double blind placebo-controlled food challenge (DBPCFC) * Written informed consent from parent/guardian * Written assent from subjects above the age of 7 Exclusion Criteria: * • History of a chronic disease (other than asthma, allergic rhinitis, and atopic dermatitis) that is at significant risk of becoming unstable or requiring a change in chronic therapeutic regimen * History of mast cell disease * History of recurrent idiopathic or virally induced urticaria, angioedema or anaphylaxis * Any history or presence of autoimmune, cardiovascular disease, chronic lung disease (other than asthma), malignancy, psychiatric illness, or gastrointestinal inflammatory conditions, including celiac disease, inflammatory bowel disease, eosinophilic esophagitis or other eosinophilic gastrointestinal disease * Current participation in any other interventional study * Subject who has undergone any type of oral immunotherapy * Severe asthma or uncontrolled mild to moderate asthma * Uncontrolled atopic dermatitis * Current use of oral steroid medications * Use of \>1 bursts of oral steroid medications in the past year * Inability to eat by mouth the fiber supplementation or placebo control and peanut flour for any reason * Use of any therapeutic antibody (biologic medication) or any immunomodulatory medication in the past 12 month (other than a short course of oral steroids) * Current use of any type of immunotherapy * Pregnancy or lactation * Allergy to potato or corn oat or cow's milk * Unwillingness to carry an epinephrine auto-injector * Unwillingness to comply with activity restrictions during OIT or any other study procedure
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Peanut allergy are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Comer Children's Hospital
Chicago, Illinois, 60637, United States
-
University of Chicago- Department of Pediatrics
Hyde Park, Illinois, 60637, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Peanut allergy patch: a new hope for kids?
- A pill that could outsmart food allergies? trial tests remibrutinib
- Peanut allergy cure in sight? trial tests tolerance in teens
- Can a shot tame peanut allergies? small study tests xolair
- Can allergy drugs help kids tolerate peanut and more?
- Peanut allergy patch enters human safety trials